Cytokinetics regains rights to to omecamtiv mecarbil, a proposed treatment for heart failure and to AMG 594 from Amgen.

Cytokinetics, Incorporated announced that Amgen has elected to terminate the Collaboration and Option Agreement, dated December 20, 2006 between the companies and thereby end its collaboration with Cytokinetics, effective May 20, 2021, and intends to transition development and commercialization rights for omecamtiv mecarbil and AMG 594 to Cytokinetics. Omecamtiv mecarbil is an investigational cardiac myosin activator, developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF), and was recently studied in GALACTIC-HF, a positive Phase III cardiovascular outcomes clinical trial. AMG 594, a novel mechanism cardiac troponin activator, is in Phase 1 development for HFrEF and other types of heart failure.